Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov;88(5):712-9.
doi: 10.1038/clpt.2010.130. Epub 2010 Jul 28.

Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy

A K Pau  1 , S D Boyd
Affiliations

Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy

A K Pau et al. Clin Pharmacol Ther. 2010 Nov.

Abstract

Combination antiretroviral therapy (cART) has improved survival rates in HIV-infected patients; however, patients now experience comorbidities that require pharmacological intervention, thereby increasing the risk of drug-drug interactions (DDIs). HIV protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and the CCR5 antagonist maraviroc are primarily metabolized via the cytochrome P450 (CYP) system and are prone to pharmacokinetic interactions.(1,2) This article addresses some key challenges that prescribers face when using available drug interaction-data resources in making day-to-day clinical decisions.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial conflict of interest.

References

    1. Pau AK. Clinical management of drug interaction with antiretroviral agents. Curr Opin HIV AIDS. 2008;3:319–324. - PubMed
    1. Seden K, Back D, Khoo S. Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. J Antimicrob Chemother. 2009;64:5–8. - PubMed
    1. Beique L, Giguere P, la Porte C, Angel J. Interactions between protease inhibitors and acid-reducing agents: a systematic review. HIV Med. 2007;8:335–345. - PubMed
    1. Guiard-Schmid JB, Poirier JM, Bonnard P, Meynard JL. Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir. J Acquir Immune Defic Syndr. 2006;41:393–394. author reply 4. - PubMed
    1. Sahloff EG, Duggan JM. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors. Ann Pharmacother. 2006;40:1731–1736. - PubMed

Publication types

Substances